Literature DB >> 23317199

Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population.

Yong-Qiang Ren1, Ju-Qiang Han, Jian-Biao Cao, Shao-Xiang Li, Gong-Ren Fan.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma (HCC).
METHODS: A total of 689 HCC patients and 680 cancer-free subjects were enrolled. Human MDR1 gene polymorphisms were investigated by created restriction site- polymerase chain reaction (CRS-PCR) and DNA sequencing methods. Multiple logistic regression models were applied to estimate the association between MDR1 gene polymorphisms and susceptibility to HCC.
RESULTS: We detected a novel c.4125A>C polymorphism and our findings suggested that this variant was significantly associated with susceptibility to HCC. A significantly increased susceptibility to HCC was noted in the homozygote comparison (CC versus AA: OR=1.621, 95% CI 1.143-2.300, χ2=7.4095, P=0.0065), recessive model (CC versus AC+AA: OR=1.625, 95% CI 1.167-2.264, χ2=8.3544, P=0.0039) and allele contrast (C versus A: OR=1.185, 95% CI 1.011-1.389, χ2=4.4046, P=0.0358). However, no significant increase was observed in the heterozygote comparison (AC versus AA: OR=0.995, 95% CI 0.794-1.248, χ2=0.0017, P=0.9672) and dominant model (CC+AC versus AA: OR=1.106, 95% CI 0.894-1.369, χ2=0.8560, P=0.3549).
CONCLUSIONS: These findings suggest that the c.4125A>C polymorphism of the MDR1 gene might contribute to susceptibility to HCC in the Chinese population. Further work will be necessary to clarify the relationship between the c.4125A>C polymorphism and susceptibility to HCC on larger populations of diverse ethnicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23317199     DOI: 10.7314/apjcp.2012.13.11.5451

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma.

Authors:  Zhi-Chao Wang; Long-Zi Liu; Xin-Yang Liu; Jin-Jing Hu; Yong-Na Wu; Jie-Yi Shi; Liu-Xiao Yang; Meng Duan; Xiao-Ying Wang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Tumour Biol       Date:  2015-04-12

2.  Polymorphisms of xenobiotic-metabolizing and transporter genes, and the risk of gastric and colorectal cancer in an admixed population from the Brazilian Amazon.

Authors:  Amanda Nazaré Cohen Lima de Castro; Marianne Rodrigues Fernandes; Darlen Cardoso de Carvalho; Tatiane Piedade de Souza; Juliana Carla Gomes Rodrigues; Roberta Borges Andrade; Antonio Andre Conde Modesto; Sidney Santos; Paulo Pimentel Assumpção; Ney Pereira Carneiro Dos Santos
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

3.  Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese.

Authors:  Wen Qiao; Tao Wang; Li Zhang; Qing Tang; Dan Wang; Hongkun Sun
Journal:  Med Oncol       Date:  2013-06-26       Impact factor: 3.064

Review 4.  Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.

Authors:  Loraine Kay D Cabral; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

5.  Association of C3435T, C1236T and C4125A Polymorphisms of the MDR-1 Gene in Egyptian Children with Acute Lymphoblastic Leukaemia

Authors:  Roba M Talaat; Medhat Y K El-Kelliny; Basima A El-Akhras; Rania M Bakry; Khaled F Riad; Adel A Guirgis
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26

6.  LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells.

Authors:  Yunhao Chen; Hui Zhao; Haibo Li; Xiao Feng; Hui Tang; Chunhui Qiu; Jianwen Zhang; Binsheng Fu
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-13       Impact factor: 8.886

Review 7.  Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Authors:  Sara M Atwa; Margarete Odenthal; Hend M El Tayebi
Journal:  Cancers (Basel)       Date:  2021-08-27       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.